Comparative Pharmacology
Head-to-head clinical analysis: PROPYLTHIOURACIL versus THYROSAFE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPYLTHIOURACIL versus THYROSAFE.
PROPYLTHIOURACIL vs THYROSAFE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propylthiouracil (PTU) inhibits thyroid peroxidase, thereby blocking the synthesis of thyroid hormones. It also inhibits the peripheral conversion of thyroxine (T4) to triiodothyronine (T3).
THYROSAFE is a thyroid hormone replacement therapy containing levothyroxine, a synthetic T4 hormone. It exerts its physiological effects by binding to thyroid hormone receptors (TRα and TRβ) in target tissues, modulating gene transcription and cellular metabolism.
Oral, 300-600 mg/day in 3 divided doses until euthyroid; then 50-150 mg/day as maintenance.
Initial: 0.075 mg orally once daily; adjust dose every 2-4 weeks based on TSH. Typical maintenance dose: 0.05-0.15 mg orally once daily.
None Documented
None Documented
Clinical Note
moderatePropylthiouracil + Clozapine
"The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Clozapine."
Clinical Note
moderateWarfarin + Propylthiouracil
"Warfarin may decrease the anticoagulant activities of Propylthiouracil."
Clinical Note
moderatePhenprocoumon + Propylthiouracil
"Phenprocoumon may decrease the anticoagulant activities of Propylthiouracil."
Clinical Note
moderatePhenindione + Propylthiouracil
Terminal elimination half-life is 1-2 hours in euthyroid patients, but may be prolonged to 2-5 hours in hyperthyroid patients due to altered metabolism and thyroid status. Clinical effect persists longer than half-life due to inhibition of thyroid peroxidase.
Terminal elimination half-life is 12-18 hours (mean 15 hours). In hyperthyroidism, clearance may be increased; in renal impairment, half-life prolonged.
Primarily renal (approximately 35% as unchanged drug within 24 hours; remainder as inactive metabolites). Minor biliary/fecal elimination (<5%).
Primarily renal (60-80%) as unchanged drug; 20-40% as glucuronide conjugates; minimal biliary/fecal (<5%).
Category D/X
Category C
Antithyroid Agent
Antithyroid Agent
"Phenindione may decrease the anticoagulant activities of Propylthiouracil."